THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG

Translated title of the contribution: Follow-up during theophyllin treatment with daily evening dose in patients with sleep related breathing disorders

E. Grieger, Hartmut Schneider, U. Weichler, J. H. Peter, P. von Wichert, K. Voigt

Research output: Contribution to journalArticle

Abstract

We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60%, over the total period at least 25%). No patient had a responder type II profile. 13 patients were non-responders (improvement in initial AI and over the whole period not more than 25%, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophylline leading to discontinuation of the treatment course occurred in 5 patients. 22 Patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. However, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.

Original languageGerman
Pages (from-to)166-169
Number of pages4
JournalPneumologie
Volume47
Issue numberSUPPL. 1
StatePublished - 1993
Externally publishedYes

Fingerprint

Sleep
Respiration
Apnea
Sleep Apnea Syndromes
Therapeutics
Emotions
Theophylline
Prospective Studies

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Grieger, E., Schneider, H., Weichler, U., Peter, J. H., von Wichert, P., & Voigt, K. (1993). THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG. Pneumologie, 47(SUPPL. 1), 166-169.

THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG. / Grieger, E.; Schneider, Hartmut; Weichler, U.; Peter, J. H.; von Wichert, P.; Voigt, K.

In: Pneumologie, Vol. 47, No. SUPPL. 1, 1993, p. 166-169.

Research output: Contribution to journalArticle

Grieger, E, Schneider, H, Weichler, U, Peter, JH, von Wichert, P & Voigt, K 1993, 'THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG', Pneumologie, vol. 47, no. SUPPL. 1, pp. 166-169.
Grieger, E. ; Schneider, Hartmut ; Weichler, U. ; Peter, J. H. ; von Wichert, P. ; Voigt, K. / THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG. In: Pneumologie. 1993 ; Vol. 47, No. SUPPL. 1. pp. 166-169.
@article{53a431eb486d48be9c4d14941cd7e591,
title = "THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG",
abstract = "We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60{\%}, over the total period at least 25{\%}). No patient had a responder type II profile. 13 patients were non-responders (improvement in initial AI and over the whole period not more than 25{\%}, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophylline leading to discontinuation of the treatment course occurred in 5 patients. 22 Patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. However, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.",
author = "E. Grieger and Hartmut Schneider and U. Weichler and Peter, {J. H.} and {von Wichert}, P. and K. Voigt",
year = "1993",
language = "German",
volume = "47",
pages = "166--169",
journal = "Pneumologie",
issn = "0934-8387",
publisher = "Georg Thieme Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - THERAPIEKONTROLLE UNTER THEOPHYLLIN IN ABENDLICHER DOSIERUNG BEI PATIENTEN MIT SCHLAFBEZOGENEN ATMUNGSSTORUNGEN (SBAS) - VERLAUFSBEOBACHTUNG

AU - Grieger, E.

AU - Schneider, Hartmut

AU - Weichler, U.

AU - Peter, J. H.

AU - von Wichert, P.

AU - Voigt, K.

PY - 1993

Y1 - 1993

N2 - We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60%, over the total period at least 25%). No patient had a responder type II profile. 13 patients were non-responders (improvement in initial AI and over the whole period not more than 25%, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophylline leading to discontinuation of the treatment course occurred in 5 patients. 22 Patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. However, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.

AB - We conducted a prospective study to perform classification according to responder types and follow-up during theophyllin treatment (500 mg/d) in a group of (up to now) 65 patients suffering from sleep apnoea. Changes in the apnoea index (AI) and clinical symptoms were taken as response criteria. A significant AI reduction was seen during a follow-up period of 3 months. At the last control measurement after 6 months no significant change has been detected so far. 10 patients were classified as Type I responders (improvement in initial AI 60%, over the total period at least 25%). No patient had a responder type II profile. 13 patients were non-responders (improvement in initial AI and over the whole period not more than 25%, no improvement in the pattern of clinical symptoms). 13 patients dropped out of the trial due to non-compliance. Side effects typical of theophylline leading to discontinuation of the treatment course occurred in 5 patients. 22 Patients have not yet completed the course at the time of writing. Standardised questioning of patients showed a definite improvement in feeling tone, especially with regard to the tendency to fall asleep during the day and refreshed feeling in the morning. Nocturnal complaints occurred in only a few isolated cases. However, administration of theophyllin retard preparations in evening doses of 500 mg/d remains a meaningful therapeutic approach to sleep apnoea.

UR - http://www.scopus.com/inward/record.url?scp=0027467733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027467733&partnerID=8YFLogxK

M3 - Article

VL - 47

SP - 166

EP - 169

JO - Pneumologie

JF - Pneumologie

SN - 0934-8387

IS - SUPPL. 1

ER -